{
    "paper_id": "aa39ec2d3d5a1170b7f04ae53da6c042602ff41e",
    "metadata": {
        "title": "Journal Pre-proof COVID-19 pandemic -A focused review for clinicians COVID-19 Pandemic -a focused review for clinicians 1 2 3 4",
        "authors": [
            {
                "first": "Muge",
                "middle": [],
                "last": "Cevik",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of St Andrews",
                    "location": {
                        "addrLine": "10",
                        "country": "UK"
                    }
                },
                "email": ""
            },
            {
                "first": "Connor",
                "middle": [],
                "last": "Bamford",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Wellcome-Wolfson Institute for Experimental Medicine",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Antonia",
                "middle": [],
                "last": "Ho",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Glasgow",
                    "location": {
                        "settlement": "Glasgow",
                        "country": "UK"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "The first cases of atypical pneumonia of unidentified aetiology were reported on December 30, 2019, 57 from Wuhan, China. By January 7, 2020, a novel betacoronavirus, severe acute respiratory syndrome 58 coronavirus (SARS-CoV-2) was identified, while the disease has been named COVID-19. 59 has now been declared a pandemic, affected nearly every country, with over 2.3 million confirmed 60 cases and >160,000 deaths. The initial clinical case series from China largely comprised of 61 hospitalised patients with severe pneumonia. Further data suggested that approximately 80% patients 62 have mild disease, 20% require hospital admission, and approximately 5% require intensive care 63 admission [1] . Mortality rates are higher among people over 60 years and with coexisting conditions; 64 hypertension, diabetes and cardiovascular disease being the most common. Here we provide an haemorrhagic strokes, as well as muscle injury, have also been reported [19] . A third of patients 111 reported taste or olfactory disorders in a small Italian cohort, including anosmia [20] . Other 112 extrapulmonary manifestations include skin and ocular manifestations. An Italian study reported 113 cutaneous manifestations in 20% patients [21] . Lastly, ocular manifestations consistent with 114 conjunctivitis was reported in 32% COVID patients in a Chinese case series [22] .",
            "cite_spans": [
                {
                    "start": 697,
                    "end": 700,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 956,
                    "end": 960,
                    "text": "[19]",
                    "ref_id": null
                },
                {
                    "start": 1070,
                    "end": 1074,
                    "text": "[20]",
                    "ref_id": null
                },
                {
                    "start": 1228,
                    "end": 1232,
                    "text": "[21]",
                    "ref_id": null
                },
                {
                    "start": 1360,
                    "end": 1364,
                    "text": "[22]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "56"
        },
        {
            "text": "The estimated mean incubation period is reported as 3-6 days (range 1.3-11.3) [12] . The duration 117 from symptom onset to dyspnoea was 5-6 days [13, 17] On average, disease progresses further 118 requiring hospitalisation at 7-8 days from symptom onset. Patients may initially appear relatively 119 stable, but they often rapidly deteriorate with severe hypoxia [13, 17] . The key feature seen in these 120 cases is acute respiratory distress syndrome (ARDS) [13, 17] ",
            "cite_spans": [
                {
                    "start": 78,
                    "end": 82,
                    "text": "[12]",
                    "ref_id": null
                },
                {
                    "start": 146,
                    "end": 150,
                    "text": "[13,",
                    "ref_id": null
                },
                {
                    "start": 151,
                    "end": 154,
                    "text": "17]",
                    "ref_id": null
                },
                {
                    "start": 364,
                    "end": 368,
                    "text": "[13,",
                    "ref_id": null
                },
                {
                    "start": 369,
                    "end": 372,
                    "text": "17]",
                    "ref_id": null
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "[13,",
                    "ref_id": null
                },
                {
                    "start": 466,
                    "end": 469,
                    "text": "17]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "116"
        },
        {
            "text": "These findings suggest that patients may continue to shed RNA in various samples for a long period, 212 but this does not equate to infectiousness potential (Table 1) . This supports the current guidance of 7-213 14 days self-isolation from symptom onset. Certain hospitals following a protocol to confirm viral 214 clearance prior to transfer out of dedicated COVID-19 wards, however, this may not be required ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 157,
                    "end": 166,
                    "text": "(Table 1)",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "211"
        },
        {
            "text": "A wealth of data has been generated already on COVID-19 since early January 2020. Nevertheless, 299 key questions remain regarding understanding the population at risk and age groups, proportion of 300 individuals that have had asymptomatic infections and their transmission potential, endemicity and 301 seasonality of COVID-19, and whether stringent physical distancing measures will be effective in countries outside China. The main challenge in managing COVID19 remains the patient density, 303 however, accurate diagnoses as well as early identification and management of high-risk severe cases 304 remains a daily battle for many clinicians. For improved management of cases, there is a need to 305 understand test probability of serology, qRT-PCR and radiological testing, and the efficacy of 306 available treatment options that could be used in severe cases with high risk of mortality. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "298"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "SARS-CoV-2 infection in 86 healthcare workers in two 43",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kluytmans",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Buiting",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pas",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Detection of SARS-CoV-2 in Different Types of Clinical 419 Specimens",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Novel Coronavirus can be detected in urine, blood, anal 421 swabs and oropharyngeal swabs samples",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "422",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 423 Infected Patients",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Ruan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "New England Journal of Medicine",
            "volume": "382",
            "issn": "12",
            "pages": "1177--1186",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Viral dynamics in mild and severe cases of COVID-19",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L-M",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The 425 Lancet Infectious Diseases",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Characteristics of pediatric SARS-CoV-2 infection and potential 427 evidence for persistent fecal viral shedding",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature Medicine",
            "volume": "428",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "The reproductive number of COVID-19 is 429 higher compared to SARS coronavirus",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Gayle",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wilder-Smith",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rockl\u00f6v",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Travel Medicine",
            "volume": "27",
            "issn": "2",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2",
            "authors": [],
            "year": 2020,
            "venue": "Emerg Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Estimates of the reproduction 434 number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Biggerstaff",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Cauchemez",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Reed",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gambhir",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Finelli",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Early dynamics of transmission and control of 437 COVID-19: a mathematical modelling study. The Lancet Infectious Diseases",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Kucharski",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "W"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Diamond",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "438",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Incubation period of 2019 novel coronavirus",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Backer",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Klinkenberg",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wallinga",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "2019--439",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "nCoV) infections among travellers from Wuhan",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) 442 disease in Korea",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ki",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Epidemiol Health",
            "volume": "42",
            "issn": "0",
            "pages": "2020007--2020007",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Infections in Residents of a Long-Term Care Skilled Nursing Facility -King County",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Presymptomatic Transmission of 450",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "E"
                    ],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Chiew",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Yong",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Toh",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "J"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Superspreading SARS events",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Ning",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Emerg Infect 453 Dis",
            "volume": "10",
            "issn": "2",
            "pages": "256--60",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Middle East respiratory syndrome 455 coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and 456 public health implications",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "E"
                    ],
                    "last": "Tandi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Moon",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Hosp Infect",
            "volume": "95",
            "issn": "2",
            "pages": "207--220",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Comparative therapeutic efficacy of remdesivir and 458 combination lopinavir, ritonavir, and interferon beta against MERS-CoV",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "P"
                    ],
                    "last": "Sheahan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Sims",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Leist",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Commun",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 461",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Severe Covid-19",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Coronavirus Susceptibility to the Antiviral 66",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Agostini",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Andres",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Sims",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "In vitro inhibition of severe acute 474 respiratory syndrome coronavirus by chloroquine",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Keyaerts",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Vijgen",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Maes",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Neyts",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Van Ranst",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Biochem Biophys Res Commun",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "In Vitro Antiviral Activity and Projection of Optimized Dosing 477 Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome 478",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yao",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "SARS-CoV-2)",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "D"
                    ],
                    "last": "Chen Jun",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Liu Ping",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Xu Qingnian",
                    "suffix": ""
                },
                {
                    "first": "Ling",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Yun",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Huang Dan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Clin Infect Dis",
            "volume": "2",
            "issn": "",
            "pages": "237--479",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "A pilot study 481 of hydroxychloroquine in treatment of patients with common coronavirus disease-19 482 (COVID-19)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Shuli",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhang Dandan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "I"
                    ],
                    "last": "Zhiping",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Tao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "U"
                    ],
                    "last": "Shen Yinzhong",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hongzhou",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Zhejiang Univ (Med Sci)",
            "volume": "49",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "The potential role of IL-6 in monitoring severe case of 484 coronavirus disease",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "",
            "volume": "485",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Use of siltuximab in patients with COVID-19 486 pneumonia requiring ventilatory support",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gritti",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Raimondi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Ripamonti",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "",
            "volume": "487",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Infectious Diseases Society of America Guidelines on the Treatment and 491 Management of Patients with COVID-19",
            "authors": [
                {
                    "first": "*",
                    "middle": [],
                    "last": "Ytter",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Effectiveness of convalescent plasma therapy in severe COVID-494 19 patients",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Proceedings of the National Academy of Sciences",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "148and fungal co-infections with SARS-CoV-2 have been documented especially in the ICU setting, 149 including Acinetobacter baumanii and Klebsiella pneumoniae[28]. Among 191 patients, non-150 survivors were more likely to have sepsis based on qSOFA score and secondary infection, although 151 detailed bacteriology results were not reported[13]. Secondary infection and positive association 152 between steroid administration and secondary infection should be explored further. genome sequence for SARS-CoV-2 was released on virological.org on 10 January (GenBank 156 accession number MN908947). This allowed the rapid development of several sensitive and specific 157 qRT-PCR assays[29]. Many laboratories worldwide are now able to test for SARS-CoV-2. Assays 158 have been described that detect <10 copies of SARS-CoV-2 per reaction and will not cross-react with 159 SARS-CoV or other human coronaviruses[29]. However, sensitivity and specificity of these tests160 remain unknown and there is no clear consensus on which is preferred. 161 162 Viral RNA loads by qRT-PCR were substantially higher in sputum compared to throat swabs [3, 30, 163 31], suggesting that the type of sample may also influence the outcome of the test. Therefore, 164 currently submission of both lower and upper respiratory tracts samples is advised. Precise molecular detection is hampered by the variability in viral loads in the upper respiratory tract, 167 especially at later stages of infection. In a study from China, among 241 COVID-19 patients with at 168 least one positive SARS-CoV-2 qRT-PCR test result, in the first test, 384 (63.0%) were negative [32]. 169 In addition, several tests at different points were variable from the same patients during the course of 170 diagnosis and treatment.[32]. Therefore, a single positive test should be confirmed by a second qRT-171 PCR assay targeting a different SARS-CoV-2 gene. Although, similar studies in Taiwan and Hong 172 Kong reported less false-negatives[33]. Secondly, a single negative SARS-CoV-2 test (especially if 173 from upper respiratory tract specimen) or a positive test result for another respiratory pathogen result 174 should not be used to exclude COVID-19 infection. These findings indicate that qRT-PCR has low 175 probability of ruling out an infection and in clinically high suspicious cases repeat sampling and also 176 CT images may need to be used to guide the diagnosis. 177 178 Antibody-based methods to detect seroconversion in serum or plasma based upon enzyme-linked 179 immunosorbent assays (ELISA), indirect-immunofluorescence or virus neutralisation have been 180 reported [34-36]. Around 40-50% patients develop an antibody response to SARS-CoV-2 infection 181 after 7 days, and the majority by 14 days [35, 37]. S1 has been shown to be more specific than S as an 182 antigen for SARS-CoV-2 in serological diagnosis [36]. The commercial S1 IgG and IgA assays have 183 lower specificity but IgA showing higher sensitivity [36]. Recently, an ELISA assay based on 184 detection of recombinant S protein by serum antibodies demonstrated robust and scalable 185 determination of seroconversion that will facilitate screening of potential exposed individuals for 186 evidence of past infection [38]. Since seroconversion occurs relatively late in infection, rapid antibody 187 tests have a limited role in the diagnosis of acute infection; qRT-PCR remains the 'gold standard'. 188 189 There is an ongoing work to understand protective antibody level and immunological marker. Among 190 not develop NAbs thereafter. These results highlight that some patients with SARS-CoV-2 would recover without developing high titers of virus-specific NAbs. These findings have some implications 195 for vaccine development and also for convalescent plasma treatment as the donor plasma should be 196 titrated before use in passive therapy. There is less information available on the T cell response during 197 SARS-CoV-2 infection and how it correlates with the NAb titres. 198 199 Duration of viral shedding and isolation period 200 SARS-CoV-2 RNA has been identified by qRT-PCR in respiratory tract samples 1-2 days prior to 201 symptom onset and can persist for 7-12 days in moderate cases, and up to 2 weeks in severe cases [35, 202 40]. SARS-CoV-2 has also been detected in whole blood [41], saliva [42], faeces [43], and urine [44] 203 by qRT-PCR(Table 1).. In several case series with serial sampling, viral loads were highest soon after 204 symptom onset[35, 45]. Patients with severe COVID-19 had significantly higher viral load and 205 longer period of viral shedding than mild cases[46]. Prolonged viral RNA shedding has been reported 206 from throat swabs up to 37 days among adult patients[13], and in faeces, for over one month after 207 illness onset in children[40, 47]. However, detection of viral RNA by qRT-PCR does not necessarily 208 equate with infectious virus. No live virus was cultured from 9 mild COVID-19 cases beyond day 8 209 after symptom onset in throat swabs or sputum despite ongoing high viral load[35]. Persistently high 210 levels of RNA were also identified in the stool of the mild cases, but no live virus was cultured[35].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "215 given the prolonged RNA shedding without the evidence of viable virus. However, whether faecal-216 oral or faecal-respiratory transmission occurs, and the role of shedding in severe cases in control measures would need to prevent >60% transmission to stop the epidemic. Of note, R 0 will 224 vary by setting, and can be substantially reduced by countermeasures, as have been observed now clear that a significant proportion of individuals with COVID-19 have very mild or no 227 symptoms. Asymptomatic infection at the time of laboratory testing have been reported [52, 53], 228 though a large proportion go on to develop symptoms. For instance, among 55 asymptomatic carriers 229 with positive qRT-PCR for SARS-CoV-2 in pharyngeal swab samples, 14 went on to develop mild, 230 39 ordinary, and 2 severe COVID-19 [54]. There have been several reports of SARS-CoV-2 231 transmission from asymptomatic or presymptomatic persons [55, 56], which poses significant 232 challenges to contact tracing. Nevertheless, the relative contribution of asymptomatic or pre-233 symptomatic transmission on the overall transmission dynamics of the pandemic remains uncertain. 234 Thus, household studies to study secondary human transmission of SARS-CoV-2 and serosurveys to 235 determine the incidence of asymptomatic and subclinical infections are needed. 236 237 A further consideration is superspreading events, whereby a small number of cases are responsible for 238 a disproportionate number of secondary cases. This was a feature of both SARS-and MERS-CoV, 239 responsible for multiple nosocomial outbreaks [57, 58]. Several superspreading events has been 240 reported for COVID-19 [17]. Rapid identification and mitigation of these events will be crucial , there are no approved antivirals for SARS-CoV-2. Several antivirals that have shown 245 promise against SARS-or MERS-CoV in vitro and in vivo are currently being evaluated in clinical 246 trials for COVID-19. Lopinavir/ritonavir (LPV/r), a protease inhibitor used as an antiretroviral, showed inconclusive findings for the treatment of SARS, but demonstrated strong in vitro and in vivo antiviral activity against MERS-CoV when combined with interferon-beta (IFNb) [59]. confirmed COVID-19 patients, no significant difference in clinical improvement, mortality 251 or viral clearance was observed between LPV/r (n=99) and standard care (n=100) arms. However, 252 treatment was instituted late in infection; median time from symptom onset to treatment was 13 days, 253 and >40% of patients had undetectable viral load before or during treatment. The results were 254 complicated by the variable use of other treatments, including interferon, glucocorticoids and 255 antibiotics. Of note, day 28 mortality was lower (not significantly) in those with early treatment (19% 256 vs. 27%) and those who received LPV/r also had lower vasopressor and non-invasive ventilation use. 257 Another promising drug is remdesivir, a novel nucleotide analogue that interferes with nsp12 258 polymerase [61]. It has shown in vitro activity against a wide range of RNA viruses including SARS 259 and MERS-CoV [62, 63], and has also demonstrated superior antiviral activity compared to LPV/r-260 IFNb against MERS-CoV in a mouse model [59]. Against SARS-CoV-2, it has shown promising 261 antiviral activity in Vero E6 cells and Huh7 cells [64]. Remdesivir has been given to a small number 262 of patients with severe COVID-19 through compassionate use, however, given the lack of 263 randomisation and control group interpretation of the findings is difficult [65]. There are ongoing 264 RCTs assessing its efficacy and safety in patients with COVID-19 worldwide, and a study in France 265 evaluating its impact on viral shedding in high and moderate risk contacts in confirmed COVIDantivirals are studied in RCTs, including favipiravir and hydroxychloroquine, which 269 has been shown to inhibit virus cell entry in vitro [66]. Hydroxychloroquine (HCQ), an analogue of 270 chloroquine, has demonstrated anti-SARS-CoV-2 activity in vitro [67]. Among a small open-label 271 non-randomised study, patients treated with HCQ and HCQ + Azithromycin showed viral load 272 reduction compared to controls. However, there has been significant concerns and ethical issues about 273 the content, the ethical approval of the trial and the peer review process prior to publication raised by 274 several physicians and also the International Society of Antimicrobial Chemotherapy. In a small RCT of HCQ (n=30), there was no change in viral load or clinical outcome after 7 targeted therapeutic options are also being explored, such as inhibition of human cytokine 281 interleukin-6 (IL-6), the abundance of which has been associated with worse prognosis [69]. A 282 preprint including 21 patients that received Tocilizumab (an IL-6 receptor inhibitor) reported 283 improvement in symptoms, hypoxaemia and CT changes in the majority of patients[70]. There are 284 ongoing RCTs evaluating tocilizumab and sarilumab, also an IL-6 receptor inhibitor. With insufficient 285 evidence of efficacy for any existing treatments, the IDSA recommends that experimental therapies 286 should only be offered to patients in the context of a clinical trial [71]. 287 288 There is no licenced vaccine to protect against COVID-19. However, a number of experimental 289 candidates are in development with some already in early clinical trials. Most vaccine candidates 290 focus on immunisation with only the S glycoprotein, which is the major target for neutralization 291 antibodies. Candidate vaccines differ in the mode of S delivery and platforms dependent on 292 recombinant protein, mRNA or viral vectored approaches are being tested. Passive immunisation 293 through transfusion of convalescent sera or plasma containing neutralizing antibodies from recovered 294 donors have been reported in several case series, with clinical improvement reported in recipients [72, 295 73]. Clinical trials evaluating convalescent plasma as treatment for severe COVID-19 are ongoing.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "CM, AH drafted the first and subsequent versions of the manuscript, and all TNCPERE. The Epidemiological Characteristics of an Outbreak of 2019 Novel",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": ". The interval from symptom onset to the 121 development of ARDS is approximately 8-12 days[13]. In addition, the incidence of cardiovascular 122 manifestations such as myocardial injury seems to be high, likely due to the systemic inflammatory 123 response and immune system disorders during disease progression[23].Illness severity and development of ARDS are associated with older age and underlying medical 126 conditions[17]. Additionally, neutrophilia, raised lactate dehydrogenase and D-dimer, lymphocyte 127 counts, CD3 and CD4 T-cell counts, AST, prealbumin, creatinine, glucose, low-density lipoprotein, 128 serum ferritin, and prothrombin time were also associated with higher risk of severe disease and symptomatic children (median age: 6.7 years) with known COVID19 contact in Wuhan Children's Hospital[25], 171 (12.3%) were SARS-CoV2-positive; 27 (15.8%) had no symptoms or radiologic 140 features of pneumonia, 33 (19.3%) had upper respiratory symptoms, and 64.9% had pneumonia.Three patients (with coexisting conditions) required intensive care and 1 death.In terms of co-infections, a pre-print examining >8000 samples of COVID-19 contacts tested for 144 SARS-CoV2 in China reported viral co-infections in 5.8% of COVID-19 positive individuals rhino/enterovirus, respiratory syncytial virus, and seasonal CoVs were most common[27]. Bacterial",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Transmission routes coronavirus</em>: The species and its viruses -a statement of the Coronavirus Study Group. Munster V. Functional assessment of cell entry and receptor usage for lineage B \u03b2coronaviruses, including 2019-nCoV. bioRxiv 2020: 2020.01.22.915660. Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. Fu W, Qian K, et al. Potent neutralization of 2019 novel coronavirus by recombinant Wang N, Corbett KS, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv 2020: 2020.02.11.944462. 348 12. Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Influenza-associated pneumonia as 349 reference to assess seriousness of coronavirus disease (COVID-19). Euro Surveill 2020; Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients 352 with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}